Robert Glassman
Director/Board Member at PHARVARIS N.V.
Net worth: 784 072 $ as of 2024-03-30
Profile
Dr. Robert H.
Glassman is an Executive Vice President-Search & Evaluation at Enavate Sciences, an Independent Non-Executive Director at Jubilant Therapeutics, Inc., an Independent Director at Tarus Therapeutics, Inc., an Independent Non-Executive Director at Pharvaris NV, a Clinical Assistant Professor at Weill Cornell Medical College and an Independent Director at Portage Biotech, Inc. He is on the Board of Directors at Jubilant Therapeutics, Inc., Umoja Biopharma, Inc., Pharvaris GmbH, Tarus Therapeutics, Inc., Pharvaris NV and Portage Biotech, Inc. Dr. Glassman was previously employed as a Vice Chairman & Managing Director by Credit Suisse Securities (USA) LLC, a Managing Director by Bank of America Merrill Lynch (New York), a Venture Partner by OrbiMed Advisors Private Equity, a Principal by Merrill Lynch & Co., Inc. /Old/, a Consultant by McKinsey & Co., Inc., and a Basic Science Investigator by The Rockefeller University.
He received his undergraduate degree from Harvard College and a doctorate degree from Harvard Medical School.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PHARVARIS N.V.
0.06% | 2024-03-31 | 33,352 ( 0.06% ) | 770 765 $ | 2024-03-30 |
PORTAGE BIOTECH INC
0.12% | 2023-03-30 | 23,637 ( 0.12% ) | 13 308 $ | 2024-03-30 |
Robert Glassman active positions
| Companies | Position | Start |
|---|---|---|
| PHARVARIS N.V. | Director/Board Member | 2020-12-31 |
| PORTAGE BIOTECH INC. | Director/Board Member | 2022-06-30 |
Tarus Therapeutics, Inc.
 Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Director/Board Member | 2020-12-31 |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Director/Board Member | 2021-01-04 |
Umoja Biopharma, Inc.
 Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Director/Board Member | 2021-01-24 |
Jubilant Therapeutics, Inc.
 Jubilant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Jubilant Therapeutics, Inc. operates as a patient-centric biopharmaceutical company. The firm uses advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. The company is headquartered in Bedminster, NJ. | Director/Board Member | 2021-01-31 |
| Weill Cornell Medical College | Corporate Officer/Principal | - |
Enavate Sciences
 Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital to support therapeutic companies in advancing medicines and enabling technologies to address patient needs. The company is based in Delaware. Enavate strives to empower a diverse portfolio of therapeutic companies to accelerate innovation through capital support and operational experience. James P. Boylan has been the CEO of the American company since 2022. | Private Equity Investor | 2022-07-10 |
Former positions of Robert Glassman
| Companies | Position | End |
|---|---|---|
Credit Suisse Securities (USA) LLC
 Credit Suisse Securities (USA) LLC Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Director/Board Member | 2020-12-31 |
| ░░░░ ░░ ░░░░░░░ ░░░░░░░ ░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░ ░░░░ ░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░ ░░░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Training of Robert Glassman
| Harvard Medical School | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| PORTAGE BIOTECH INC. | Health Technology |
| PHARVARIS N.V. | Health Technology |
| Private companies | 10 |
|---|---|
Merrill Lynch & Co., Inc. /Old/
 Merrill Lynch & Co., Inc. /Old/ Investment Banks/BrokersFinance Merrill Lynch & Co., Inc. provided wealth management, securities trading and sales, corporate finance and investment banking services. Merrill Lynch was a global trader and underwriter of securities and derivatives across a range of asset classes and serve as a strategic advisor to governments, institutions and individuals worldwide. The company was founded in 1913 and was headquartered in Charlotte, NC. | Finance |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Credit Suisse Securities (USA) LLC
Credit Suisse Securities (USA) LLC Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC provides a variety of capital raising, market making, advisory and brokerage services for governments, financial institutions, high-net-worth individuals, and corporate clients and affiliates. It is also a primary dealer in U.S. government securities and an underwriter, placement agent, and dealer for money market instruments, commercial paper, mortgage and other assetbacked securities, as well as a range of debt, equity and other convertible securities of corporations and other issuers. The company was founded on January 3, 2003 and is headquartered in New York, NY. | Finance |
OrbiMed Advisors Private Equity
 OrbiMed Advisors Private Equity Investment ManagersFinance OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London. | Finance |
| Bank of America Merrill Lynch (New York) | |
Tarus Therapeutics, Inc.
Tarus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Portage Biotech, Inc., Tarus Therapeutics, Inc. is a private company developing small molecule inhibitors of adenosine receptors for cancer immunotherapy and select non-oncology indications. The company is based in New York, NY. The company has a comprehensive portfolio of adenosine receptor antagonists in development, including both first-in-class and programs. The company was founded by Sushant Kumar and Peter R. Molloy, with Sushant Kumar serving as CEO since incorporation. Tarus Therapeutics was acquired by Portage Biotech, Inc. on July 05, 2022 for $49.20 million. | Health Technology |
Jubilant Therapeutics, Inc.
Jubilant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Jubilant Therapeutics, Inc. operates as a patient-centric biopharmaceutical company. The firm uses advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. The company is headquartered in Bedminster, NJ. | Health Technology |
Umoja Biopharma, Inc.
Umoja Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Umoja Biopharma, Inc. engages in the development of immunotherapy treatments for blood-based and organ-based tumors in adult and pediatric patients. It offers an integrated cellular immunotherapy platform comprising VivoVec in vivo delivery, RACR/CAR synthetic receptor payload and TumorTag targeting technologies that attack cancer cells. The company was founded by Michael Jensen, Philip Low, Andy Scharenberg and Ryan Crisman and is headquartered in Seattle, WA. | Health Technology |
Pharvaris GmbH
Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Health Technology |
Enavate Sciences
Enavate Sciences Financial ConglomeratesFinance Enavate Sciences is a platform created by Patient Square Capital to support therapeutic companies in advancing medicines and enabling technologies to address patient needs. The company is based in Delaware. Enavate strives to empower a diverse portfolio of therapeutic companies to accelerate innovation through capital support and operational experience. James P. Boylan has been the CEO of the American company since 2022. | Finance |
- Stock Market
- Insiders
- Robert Glassman
